Vasopeptidase inhibition: a double-edged sword?

Area of Science:

• Cardiovascular Pharmacology
• Enzyme Inhibition
• Peptide Hormone Metabolism

Background:

• Angiotensin-converting enzyme (ACE) inhibitors offer significant cardiovascular benefits by modulating peptide hormones.
• Vasopeptidase inhibition combines ACE and neutral endopeptidase (NEP) inhibition to enhance therapeutic effects.
• NEP metabolizes natriuretic peptides, suggesting combined inhibition could increase beneficial natriuretic peptide levels.

Purpose of the Study:

• To evaluate the therapeutic potential and risks of vasopeptidase inhibitors.
• To understand the complex interactions between ACE and NEP inhibition.
• To assess the impact of combined inhibition on peptide hormone metabolism and cardiovascular outcomes.

Main Methods:

• The study reviews existing literature on ACE inhibitors, NEP inhibitors, and vasopeptidase inhibitors.
• It analyzes the substrate specificities and interactions of ACE and NEP.
• Pharmacological consequences of combined inhibition on kinin, angiotensin, and endothelin peptides are examined.

Main Results:

• Combined ACE and NEP inhibition potentiates bradykinin and kallidin levels.
• It leads to increased Angiotensin II (Ang II) and potentially endothelin levels.
• Reduced Angiotensin-(1-7) [Ang-(1-7)] levels and increased angioedema risk are observed.

Conclusions:

• Vasopeptidase inhibition presents complex metabolic interactions that may counteract therapeutic benefits.
• The fixed ratio of ACE/NEP inhibition in single molecules poses challenges for dose optimization.
• Careful clinical evaluation is essential before widespread adoption of vasopeptidase inhibitors in patient care.